AR075981A1 - Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. uso - Google Patents
Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. usoInfo
- Publication number
- AR075981A1 AR075981A1 ARP100101007A ARP100101007A AR075981A1 AR 075981 A1 AR075981 A1 AR 075981A1 AR P100101007 A ARP100101007 A AR P100101007A AR P100101007 A ARP100101007 A AR P100101007A AR 075981 A1 AR075981 A1 AR 075981A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- igg1 antibody
- irinotecan
- pharmaceutical composition
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica, en particular para el uso en el cáncer, que contiene un anticuerpo IgG1 humanizado anti-EGFR y el irinotecán, en un vehículo farmacéuticamente aceptable, en la que dicho anticuerpo IgG1 humanizado anti-EGFR contiene: a) en el dominio variable de cadena larga una CDR1 de SEQ ID Ns:1, una CDR2 de SEQ ID Ns:16 y una CDR3 de SEQ ID Ns:31 y b) en el dominio variable de cadena corta una CDR1 de SEQ ID Ns:33, una CDR2 de SEQ ID Ns:34 y una CDR3 de SEQ ID Ns:35. Reivindicacion: La composicion farmacéutica de una cualquiera de las reivindicaciones de 1 a 3, que contiene además uno o más agentes anticancerosos adicionales. Reivindicacion 5: El anticuerpo IgG1 humanizado anti-EGFR y el irinotecán para el uso combinado en el tratamiento del cáncer, dicho anticuerpo IgG1 humanizado anti-EGFR contiene: a) en el dominio variable de cadena carga una CDR1 de SEQ ID Ns:1, una CDR2 de SEQ ID Ns:16 y una CDR3 de SEQ ID Ns: 31 y b) en el dominio variable de cadena corta una CDR1 de SEQ ID Ns:33, una CDR2 de SEQ ID Ns:34 y una CDR3 de SEQ ID Ns:35.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09156844 | 2009-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075981A1 true AR075981A1 (es) | 2011-05-11 |
Family
ID=42224955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101007A AR075981A1 (es) | 2009-03-31 | 2010-03-29 | Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100247533A1 (es) |
| EP (1) | EP2413965A1 (es) |
| JP (1) | JP2012518680A (es) |
| KR (1) | KR20110128320A (es) |
| CN (1) | CN102325549A (es) |
| AR (1) | AR075981A1 (es) |
| AU (1) | AU2010230346A1 (es) |
| CA (1) | CA2754646A1 (es) |
| IL (1) | IL213975A0 (es) |
| MX (1) | MX2011009620A (es) |
| SG (1) | SG174963A1 (es) |
| TW (1) | TW201039845A (es) |
| WO (1) | WO2010112413A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552903A (zh) * | 2010-12-09 | 2012-07-11 | 上海张江生物技术有限公司 | 一种抗egfr人源化单克隆抗体制剂 |
| KR20140122649A (ko) | 2011-04-21 | 2014-10-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (ADCs) 및 그의 용도 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| WO2013173255A2 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind egfr |
| CN104059148B (zh) * | 2013-03-18 | 2016-09-07 | 回而生医药科技（北京）有限公司 | 人源化抗人表皮生长因子受体抗体及其应用 |
| CN107076750B (zh) | 2014-07-18 | 2020-06-23 | 赛诺菲 | 用于预测疑似患有癌症的患者使用阿柏西普的治疗结果的方法 |
| CA2959841A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| BR112017027813A2 (pt) | 2015-06-22 | 2018-08-28 | Bayer Pharma Aktiengesellschaft | conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017162663A1 (de) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| CN109310781A (zh) | 2016-06-15 | 2019-02-05 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
| WO2020136145A2 (en) | 2018-12-26 | 2020-07-02 | Innate Pharma | Leucocyte immunoglobulin-like receptor neutralizing antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| HU219537B (hu) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| WO2004000102A2 (en) | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1587921B1 (en) | 2003-01-22 | 2010-07-28 | GlycArt Biotechnology AG | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| RS59761B1 (sr) * | 2005-02-07 | 2020-02-28 | Roche Glycart Ag | Antigen vezujući molekuli, koji vezuju egfr, vektori koji kodiraju iste, i njihova upotreba |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
-
2010
- 2010-03-26 MX MX2011009620A patent/MX2011009620A/es not_active Application Discontinuation
- 2010-03-26 SG SG2011070679A patent/SG174963A1/en unknown
- 2010-03-26 JP JP2011551500A patent/JP2012518680A/ja active Pending
- 2010-03-26 EP EP10711062A patent/EP2413965A1/en not_active Withdrawn
- 2010-03-26 CN CN2010800087359A patent/CN102325549A/zh active Pending
- 2010-03-26 AU AU2010230346A patent/AU2010230346A1/en not_active Abandoned
- 2010-03-26 KR KR1020117022747A patent/KR20110128320A/ko active IP Right Grant
- 2010-03-26 WO PCT/EP2010/053973 patent/WO2010112413A1/en active Application Filing
- 2010-03-26 CA CA2754646A patent/CA2754646A1/en not_active Abandoned
- 2010-03-29 AR ARP100101007A patent/AR075981A1/es unknown
- 2010-03-29 US US12/748,506 patent/US20100247533A1/en not_active Abandoned
- 2010-03-30 TW TW099109715A patent/TW201039845A/zh unknown
-
2011
- 2011-07-07 IL IL213975A patent/IL213975A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110128320A (ko) | 2011-11-29 |
| MX2011009620A (es) | 2011-10-19 |
| WO2010112413A1 (en) | 2010-10-07 |
| CA2754646A1 (en) | 2010-10-07 |
| JP2012518680A (ja) | 2012-08-16 |
| AU2010230346A1 (en) | 2011-07-28 |
| CN102325549A (zh) | 2012-01-18 |
| US20100247533A1 (en) | 2010-09-30 |
| IL213975A0 (en) | 2011-08-31 |
| EP2413965A1 (en) | 2012-02-08 |
| TW201039845A (en) | 2010-11-16 |
| SG174963A1 (en) | 2011-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075981A1 (es) | Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. uso | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| CL2020001579A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) | |
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| PE20090227A1 (es) | Composiciones farmaceuticas que comprenden agentes anti-beta-klotho | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
| PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| CR10308A (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| AR084315A1 (es) | Anticuerpos anti-notch1 | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| ES2722824T3 (es) | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) | |
| AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| PE20130214A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |